Esperion Therapeutics
ESPR
ESPR
139 hedge funds and large institutions have $299M invested in Esperion Therapeutics in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
12.7% less ownership
Funds ownership: 100.53% → 87.84% (-13%)
19% less call options, than puts
Call options by funds: $9.22M | Put options by funds: $11.4M
50% less capital invested
Capital invested by funds: $598M → $299M (-$299M)
Holders
139
Holding in Top 10
1
Calls
$9.22M
Puts
$11.4M
Top Buyers
| 1 | +$3.06M | |
| 2 | +$2.31M | |
| 3 | +$2.23M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.92M |
| 5 |
Millennium Management
New York
|
+$1.81M |
Top Sellers
| 1 | -$20.2M | |
| 2 | -$10.6M | |
| 3 | -$8.46M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$7.86M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$6.12M |